Roflumilast for the treatment of chronic obstructive pulmonary disease

Current Opinion in Investigational Drugs

Volumn 7, Issue 5, 2006, Pages 412-417

  Antoniu, Sabina A ^a  

^a Clinic of Pulmonary Disease   (Romania)

Author keywords

Airway; Chronic obstructive pulmonary disease; COPD; Efficacy; Inflammation; Phosphodiesterase 4 inhibitors; Safety

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CILOMILAST; CORTICOSTEROID; FLUTICASONE; LONG ACTING DRUG; METHYLXANTHINE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; ROFLUMILAST; SILDENAFIL; THEOPHYLLINE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BRONCHODILATING ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COUGHING; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DRUG SAFETY; DRUG STRUCTURE; DYSPNEA; GRAND MAL EPILEPSY; HEADACHE; HEART ARRHYTHMIA; HUMAN; INFLAMMATION; INSOMNIA; LUNG FUNCTION; NAUSEA; NONHUMAN; RHINOPHARYNGITIS; SMOKING; SMOKING CESSATION; SPUTUM;

EID: 33646847170     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. The GOLD Workshop Report: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. (2005) September. http://www.goldcopd.com
2. Lung Health Study Research Group: Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med (2000) 343(26):1902-1909.
3. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK: Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. Br Med J (2000) 320(7245):1297-1303.
4. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H: Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J (2003) 22(6):912-919.
5. Jones PW: Clinical effects of inhaled corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc (2004) 1(3):167-170.
6. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV: Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med (1999) 340(25):1948-1953.
7. Sutherland ER, Alimers H, Ayas NT, Venn AJ, Martin RJ: Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: A meta-analysis. Thorax (2003) 58(11):937-941.
8. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K: Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial. Lancet (1999) 353(9167):1819-1823.
9. 2 Agonists Study Group: Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial. Lancet (2003) 361(9356):449-456.
10. Banner KH, Page CP: Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma. Eur Respir J (1995) 8(6):996-1000.
11. Barnes PJ: Theophylline in chronic obstructive pulmonary disease: New horizons. Proc Am Thorac Soc (2005) 2(4):334-339; discussion 340-341.
12. MacNee W: Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc (2005) 2(4):258-266; discussion 290-291.
13. Stockley RA: Neutrophils and the pathogenesis of COPD. Chest (2002) 121(5 Suppl):151S-155S.
14. Russell RE, Thorley A, Culpitt SV, Dodd S, Donnelly LE, Demattos C, Fitzgerald M, Barnes PJ: Alveolar macrophage-mediated elastolysis: Roles of matrix metalloproteinases, cysteine, and serine proteases. Am J Physiol Lung Cell Mol Physiol (2002) 283(4):L867-L873.
15. Lacoste JY, Bousquet J, Chanez P, Van Vyre T, Simony-Lafontaine J, Lequeu N, Vic P, Enander I, Godard P, Michel FB: Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol (1993) 92(4):537-548.
16. Saetta M, Di Stefano A, Maestrelli P, Turato G, Ruggieri MP, Roggeri A, Calcagni P, Mapp CE, Ciaccia A, Fabbri LM: Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med (1994) 150(6 Pt 1):1646-1652.
17. Cosio MG, Majo J. Cosio MG: Inflammation of the airways and lung parenchyma in COPD: Role of T cells. Chest (2002) 121(5 Suppl):160S-165S.
18. Majo J, Ghezzo H, Cosio MG: Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J (2001) 17(5):946-953.
19. Saetta M, Di Stefano A, Turato G, Facchini FM, Corbino L, Mapp CE, Maestrelli P, Ciaccia A, Fabbri LM: CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 157(3 Pt 1):822-826.
20. O'Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK: Inflammation in bronchial biopsies of subjects with chronic bronchitis: Inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med (1997) 166(3):852-857.
21. Di Stefano A, Capelli A, Lusuardi M, Caramori G, Balbo P, Ioli F, Sacco S, Gnemmi L, Brun P, Adcock IM, Balbi B et al: Decreased T lymphocyte infiltration in bronchial biopsies of subjects with severe chronic obstructive pulmonary disease. Clin Exp Allergy (2001) 31(6):893-902.
22. Gizycki MJ, Hattotuwa KL, Barnes N, Jeffery PK: Effects of fluticasone propionate on inflammatory cells in COPD: An ultrastructural examination of endobronchial biopsy tissue. Thorax (2002) 57(9):799-803.
23. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC: The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: A double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med (2002) 165(12):1592-1596.
24. Spencer S, Calverley PM, Burge PS, Jones PW: Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J (2004) 23(5):698-702.
25. Spencer S, Calverley PM, Sherwood Burge P, Jones PW: Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2001) 163(1):122-128.
26. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H: Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J (2003) 21(1):74-81.
27. Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T: The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD. Chest (2003) 124(3):834-843.
28. Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, Zhu J, Johnson M, Thomson NC, Jeffery PK: Anti-inflammatory effects of salmeterol/ fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med (2006) 173(7):736-743.
29. Barnes PJ: Theophylline: New perspectives for an old drug. Am J Respir Crit Care Med (2003) 167(6):813-818.
30. Rabe KF, Magnussen H, Dent G: Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Eur Respir J (1995) 8(4):637-642.
31. Rabe KF, Tenor H, Dent G, Schudt C, Liebig S, Magnussen H: Phosphodiesterase isozymes modulating inherent tone in human airways: Identification and characterization. Am J Physiol (1993) 264(5 Pt 1):L458-L464.
32. McKay SE, Howie CA, Thomson AH, Whiting B, Addis GJ: Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax (1993) 48(3):227-232.
33. Murciano D, Auclair MH, Pariente R, Aubier M: A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med (1989) 320(23):1521-1525.
34. Rossi A, Kristufek P, Levine BE, Thomson MH, Till D, Kottakis J, Della Cioppa G, Formoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study Group: Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest (2002) 121(4):1058-1069.
35. Kita H, Abu-Ghazaleh RI, Gleich GJ, Abraham RT: Regulation of Ig-induced eosinophil degranulation by adenosine 3′,5′-cyclic monophosphate. J Immunol (1991) 146(8):2712-2718.
36. Scordamaglia A, Ciprandi G, Ruffoni S, Caria M, Paolieri F, Venuti D, Canonica GW: Theophylline and the immune response: In vitro and in vivo effects. Clin Immunol Immunopathol (1988) 48(2):238-246.
37. Mascali JJ, Cvietusa P, Negri J, Borish L: Anti-inflammatory effects of theophylline: Modulation of cytokine production. Ann Allergy Asthma Immunol (1996) 77(1):34-38.
38. Ali S, Mustafa SJ, Metzger WJ: Modification of allergen-induced airway obstruction and bronchial hyperresponsiveness in the allergic rabbit by theophylline aerosol. Agents Actions (1992) 37(3-4):168-170.
39. Jaffar ZH, Sullivan P, Page C, Costello J: Low-dose theophylline modulates T-lymphocyte activation in allergen-challenged asthmatics. Eur Respir J (1996) 9(3):456-462.
40. Djukanovic R, Finnerty JP, Lee C, Wilson S, Madden J, Holgate ST: The effects of theophylline on mucosal inflammation in asthmatic airways: Biopsy results. Eur Respir J (1995) 8(5):831-833.
41. Finnerty JP, Lee C, Wilson S, Madden J, Djukanovic R, Holgate ST: Effects of theophylline on inflammatory cells and cytokines in asthmatic subjects: A placebo-controlled parallel group study. Eur Respir J (1996) 9(8):1672-1677.
42. Culpitt SV, De Matos C, Russell RE, Donnelly LE, Rogers DF, Barnes PJ: Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2002) 165(10):1371-1376.
43. Kobayashi M, Nasuhara Y, Betsuyaku T, Shibuya E, Tanino Y, Tanino M, Takamura K, Nagai K, Hosokawa T, Nishimura M: Effect of low-dose theophylline on airway inflammation in COPD. Respirology (2004) 9(2):249-254.
44. Iiboshi H, Ashitani JI, Katoh S, Sano A, Matsumoto N, Mukae H, Nakazato M: Long-term treatment with theophylline reduces neutrophils, interleukin-8 and tumor necrosis factor-α in the sputum of patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther (2005) doi:10.1016/j.pupt.2005.11.008.
45. Pfizer Inc: Viagra. (2005) July. http://www.pfizer.com/pfizer/download/uspi_viagra.pdf
46. Pfizer Inc: Revatio. (2005) August. http://www.pfizer.com/pfizer/download/uspi_revatio.pdf
47. Lipworth BJ: Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet (2005) 365(9454):167-175.
48. Averill LE, Stein RL, Kammer GM: Control of human T-lymphocyte interleukin-2 production by a cAMP-dependent pathway. Cell Immunol (1988) 115(1):88-99.
49. 3H]R-(-)rolipram binding by selective inhibitors. Biochem J (1996) 318(2):425-436.
50. Kelly JJ, Barnes PJ, Giembycz MA: Characterization of phosphodiesterase 4 in guinea-pig macrophages: Multiple activities, association states and sensitivity to selective inhibitors. Br J Pharmacol (1998) 124(1):129-140.
51. Jimenez JL, Punzon C, Navarro J, Munoz-Fernandez MA, Fresno M: Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-κB and nuclear factor of activated T cells activation. J Pharmacol Exp Ther (2001) 299(2):753-759.
52. Giembycz MA, Corrigan CJ, Seybold J, Newton R, Barnes PJ: Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: Role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol (1996) 118(8):1945-1958.
53. Torphy TJ: Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents. Am J Respir Crit Care Med (1998) 157(2):351-370.
54. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R: In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther (2001) 297(1):280-290.
55. Hatzelmann A, Schudt C: Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther (2001) 297(1):267-279.
56. Kumar RK, Herbert C, Thomas PS, Wollin L, Beume R, Yang M, Webb DC, Foster PS: Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma. J Pharmacol Exp Ther (2003) 307(1):349-355.
57. Efficacy and safety of roflumilast in Japanese patients older than 40 y with chronic obstructive pulmonary disease. (2006) March 30. http://www.clinicaltrials.gov/ct/show/NCT00242294?order=3
58. Efficacy and safety of oral roflumilast taken once daily in patients older than 40 years with chronic obstructive pulmonary disease. (2006) March 07. http://www.clinicaltrials.gov/ct/show/NCT00242320?order=1
59. Long-term study of safety and efficacy of roflumilast in Japanese patients older than 40 y with chronic obstructive pulmonary disease. (2005) December 08. http://www.clinicaltrials.gov/ct/show/NCT00246935?order=5
60. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D. Bethke TD: Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: A randomised controlled trial. Lancet (2005) 366(9485):583-571.
61. Engelstatter R, Wingertzahn M, Schmid-Wirlitsch C, Bredenbroker D, Leichtl S, Wurst W: Roflumilast, an oral, once-daily phosphodiesterase 4 (PDE4) inhibitor, does not exhibit bronchodilatory activity. Ann Allergy Asthma Immunol (2005) 94:169.